Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers

Bremond-Gignac, Dominique; Daruich, Alejandra; Robert, Matthieu P.; Chiambaretta, Frédéric

doi:10.1080/13543784.2019.1677605

Cited by 26 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the effectiveness of RGTA has been demonstrated in the closure of NCU 2,20 , and for the treatment of accidental injuries (cornea burns) 21 . The RGTA matrix has also shown to be useful in the closure of corneal ulcers in an animal model of photorefractive keratectomy (PRK) surgery 22 .…”

Section: Discussionmentioning

confidence: 99%

“…The ocular surface involves structures like the cornea, limbus and conjunctiva, which protect the ocular integrity against external pathogens under normal conditions 1 . However, there are noninfectious disorders that can generate lesions with a variable severity grade from super cial keratitis to ulcers and corneal melting, which can permanently affect the visual acuity in many cases 2 .…”

Section: Introductionmentioning

confidence: 99%

“…These eye drops are composed by a polysaccharide that regulates the extracellular matrix-like heparan sulfate. RGTA has shown successful results in the treatment of several corneal surface disorders, including noninfectious ulcers 2,10 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Sánchez-Ávila

Uribe-Badillo²,

Gonzalez³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To provide the efficacy and safety of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers.Methods: This retrospective study included patients from Fernandez-Vega University Institute between 2010 and 2019, with noninfectious corneal ulcers and no response to standard treatments. RGTA treatment was firstly applied (1 drop every two days), but if ulcer closure was not achieved, PRGF eye drops treatment was added (4 times/day). The time to reach the ulcer closure; the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. The presence of adverse events along the follow-up period was also reported. Results: Seventy-four patients (79 eyes) were included in the study, forty-six eyes (62.2%) were women, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder found in the patients of the study (n = 27, 34.2%), mainly due to the herpes virus (n = 15, 19.0%). The mean time of PRGF eye drops treatment associated with RGTA matrix was 4.2 ± 2.2 (1.5 -9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved significantly from the baseline (p<0.001), while IOP remained unchanged (p=0.665). No adverse events were recorded. Conclusions: The use of RGTA and PRGF in noninfectious ulcers was effective and safe, and it could be a therapeutic alternative for this type of corneal diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Sánchez-Ávila

Uribe-Badillo²,

Gonzalez³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Additional studies have shown that cenegermin is safe and effective for use in pediatric patients ≥ 2 years old and is now permitted for use in children in the USA [49]. The most common side effects of cenegermin include eye and eyelid pain, inflammation, increased tearing, and foreign body sensation in the eye [50].…”

Section: Cenegermin (Oxervate™)mentioning

confidence: 99%

“…Regenerating agents (RGTAs) are topical agents composed of polysaccharides in a variety of specific formulations that are made to mimic natural heparan sulfates, components of the corneal extracellular matrix [49]. The polysaccharides are linked to a matrix protein and growth factors and serve to restore the balance of matrix proteins and cytokines normally bound to heparan sulfate [67].…”

Section: Regenerating Agent (Cacicol®)mentioning

confidence: 99%

Corneal Neurotization and Novel Medical Therapies for Neurotrophic Keratopathy

Rosenblatt

Sears

Park

et al. 2020

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Purpose of Review Neurotrophic keratopathy (NK) is a degenerative corneal disease characterized by decreased corneal sensibility and impaired corneal healing. In this article, we review surgical techniques for corneal neurotization (CN) and novel medical therapies for the treatment of NK. Recent Findings In recent decades, there has been a paradigm shift in the treatment strategies for NK. New minimally invasive direct and indirect CN approaches have demonstrated efficacy at improving best-corrected visual acuity and central corneal sensation while decreasing surgical morbidity. In addition, several targeted medical therapies, such as recombinant human nerve growth factor (rhNGF), regenerating agents (RGTA), and nicergoline, have shown promise in improving corneal epithelial healing. Of these options, cenegermin (Oxervate®, Dompé), a topical biologic medication, has emerged as an approved medical treatment for moderate to severe NK. Summary NK is a challenging condition caused by alterations in corneal nerves, leading to impairment in sensory and trophic function with subsequent breakdown of the cornea. Conventional therapy for NK depends on the severity of disease and focuses primarily on protecting the ocular surface. In recent years, numerous CN techniques and novel medical treatments have been developed that aim to restore proper corneal innervation and promote ocular surface healing. Further studies are needed to better understand the long-term efficacy of these treatment options, their target populations, and the potential synergistic efficacy of combined medical and surgical treatments.

show abstract

Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis

Roumeau

Dutheil

Sapin

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers

Cited by 26 publications

References 33 publications

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Corneal Neurotization and Novel Medical Therapies for Neurotrophic Keratopathy

Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis

Contact Info

Product

Resources

About